Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors-Reference-Cited by-同舟云学术

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors

Published:2019-06-14 Issue:14 Volume:62 Page:6575-6596
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lin Jian¹^ORCID,Lu Wei¹,Caravella Justin A.¹,Campbell Ann Marie¹,Diebold R. Bruce¹,Ericsson Anna¹,Fritzen Edward¹,Gustafson Gary R.¹,Lancia David R.¹,Shelekhin Tatiana¹,Wang Zhongguo¹,Castro Jennifer¹,Clarke Andrea¹,Gotur Deepali¹,Josephine Helen R.¹,Katz Marie¹,Diep Hien¹,Kershaw Mark¹,Yao Lili¹,Kauffman Goss¹,Hubbs Stephen E.¹,Luke George P.¹,Toms Angela V.¹,Wang Liann¹,Bair Kenneth W.¹,Barr Kenneth J.¹,Dinsmore Christopher¹,Walker Duncan¹,Ashwell Susan¹

Affiliation:

1. Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00362

Reference39 articles.

1. Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity

2. Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

3. Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting